David Patience - 28 Aug 2025 Form 4 Insider Report for TriSalus Life Sciences, Inc. (TLSI)

Signature
/s/ Mary Szela, Attorney-in-Fact
Issuer symbol
TLSI
Transactions as of
28 Aug 2025
Net transactions value
$0
Form type
4
Filing time
29 Aug 2025, 16:18:12 UTC
Previous filing
15 Aug 2025
Next filing
25 Nov 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Patience David Chief Financial Officer 6272 W. 91ST AVENUE, WESTMINSTER /s/ Mary Szela, Attorney-in-Fact 29 Aug 2025 0001970009

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TLSI Employee Stock Option (right to buy) Award $0 +248,899 +86% $0.000000 538,899 28 Aug 2025 Common Stock 248,899 $5.11 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the granting of stock options upon achieving or exceeding $75 million of revenue over any twelve (12) consecutive calendar month period ending on or before December 31, 2027. The options vest immediately upon achieving the performance requirement, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F2 The stock options expire on December 31, 2027 if the revenue threshold is not met.